M.-J. Jean-Pastor

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor, is widely used in association with standard chemotherapy in metastatic cancer. Well tolerated, bevacizumab is sometimes associated with serious adverse drug reactions (ADRs). The objective of this study is to describe the profile of ADRs related to bevacizumab(More)
  • 1